abstract: BACKGROUND: The term @entity1 is an early attempt to define specific endotypes of @entity0 with @entity3 , @entity2 , or both and increased IgE levels. OBJECTIVE: We performed a longitudinal analysis of the relevance of the @entity4 endotype from birth to age 13  years. METHODS: Allergic sensitization against 28 @entity5 was assessed at   , 1  , 4, 6, and 13 years of age in 399 @entity0 from the Copenhagen Prospective Study on @entity3 in Childhood2000 birth cohort by using both skin prick test responses and specific IgE levels. @entity3 and @entity2 were diagnosed longitudinally by strictly adhering to predefined algorithms. Associations between allergic sensitization, @entity3 , and @entity2 were estimated by means of logistic regression, and a machine learning approach was used to identify temporal phenotype clusters of these traits. RESULTS: Allergic sensitization showed no association with @entity3 through early childhood (0-6  years) when analyzed as any sensitization (odds ratio [OR] range, 0.78-1.29; P  >=   .48). However, at 13  years of age, any sensitization was associated with @entity3 (OR range, 4.02-5.94; all P  <  .001). In contrast, any sensitization was associated with @entity2 at   , 1  , and 6  years of age (OR range, 2.06-6.02; P   <=  .01) and borderline associated at 4  years of age (OR, 1.61 [95% CI, 0.96-2.69]; P  =  .07) but not at 13  years of age (OR, 1.57 [95% CI, 0.78-3.16]; P  =  .21). We identified 4 latent patterns of disease development that were either dominated by sensitization (37%), @entity2 (26%), @entity3 (14%), or healthy status (24%). CONCLUSION: We found very little interdependency between @entity3 , @entity2 , and allergic sensitization through childhood. The associations between those entities were strongly dependent on age, type of allergens, and method of testing for sensitization. Therefore, atopy in @entity0 is unlikely to represent a true endotype.

title: XXXX in childhood.

answer: @entity4


abstract: AIM: Our aim was to compare the different methods of treatment available for @entity3 ( @entity3 ) in the oral maxillofacial region. A classification based on clinical and immunohistochemical data is proposed and a grading for disease severity is provided. @entity0 AND METHODS: The records and clinical data of 12 @entity0 were evaluated retrospectively. The @entity0 ages ranged from 20 months to 47 years. Nine had manifestations in the maxillo-facial region, of which six had a single oral manifestation only, with the three remaining ones having multiple manifestations in this region. Three @entity0 had additional manifestations in the upper thorax (coming to a total of twelve @entity0 ). Eleven @entity0 were surgically treated with one having been treated previously with a @entity2 -therapy. One @entity0 had been treated with chemotherapy. The longest duration of follow-up was 16 years. Immunohistochemical stains for antigen-CD1a, antigen-S-100 and antigen-Ki-67 were performed. A proposal for staging the manifestations in the oromaxillo-facial-region was made. The intensity of the antigen-Ki-67 stains were evaluated. RESULTS: One @entity0 presented a relapse only implying that surgical treatment was very effective in the eradication and cure of the disorder. Eleven @entity0 exhibited no signs of recurrence. It is felt that the number of antigen-Ki-67-positive cells is related to the activity of the disease. CONCLUSION: @entity3 should be treated surgically. Only in very severe cases should surgical treatment be complimented by either radiotherapy or chemotherapy. Especially in disseminated cases, chemotherapy seems to improve the outcome. Antigen-Ki-67 as a proliferation marker is suggested as a grading parameter for @entity1 behaviour.

title: Oral XXXX : antigen-Ki-67 as a indicator for @entity1 behaviour.

answer: @entity3


abstract: AIM: Our aim was to compare the different methods of treatment available for @entity3 ( @entity3 ) in the oral maxillofacial region. A classification based on clinical and immunohistochemical data is proposed and a grading for disease severity is provided. @entity0 AND METHODS: The records and clinical data of 12 @entity0 were evaluated retrospectively. The @entity0 ages ranged from 20 months to 47 years. Nine had manifestations in the maxillo-facial region, of which six had a single oral manifestation only, with the three remaining ones having multiple manifestations in this region. Three @entity0 had additional manifestations in the upper thorax (coming to a total of twelve @entity0 ). Eleven @entity0 were surgically treated with one having been treated previously with a @entity2 -therapy. One @entity0 had been treated with chemotherapy. The longest duration of follow-up was 16 years. Immunohistochemical stains for antigen-CD1a, antigen-S-100 and antigen-Ki-67 were performed. A proposal for staging the manifestations in the oromaxillo-facial-region was made. The intensity of the antigen-Ki-67 stains were evaluated. RESULTS: One @entity0 presented a relapse only implying that surgical treatment was very effective in the eradication and cure of the disorder. Eleven @entity0 exhibited no signs of recurrence. It is felt that the number of antigen-Ki-67-positive cells is related to the activity of the disease. CONCLUSION: @entity3 should be treated surgically. Only in very severe cases should surgical treatment be complimented by either radiotherapy or chemotherapy. Especially in disseminated cases, chemotherapy seems to improve the outcome. Antigen-Ki-67 as a proliferation marker is suggested as a grading parameter for @entity1 behaviour.

title: Oral @entity3 : antigen-Ki-67 as a indicator for XXXX behaviour.

answer: @entity1


abstract: BACKGROUND: The combination of @entity7 and @entity9 has been shown to be effective in @entity0 with advanced @entity8 ( @entity8 ). Based on these data, we planned to treat @entity0 with stage IIIB @entity8 without @entity11 and/or metastatic supraclavicular lymph nodes, in order to study the potential effectiveness of this association as neoadjuvant treatment. MATERIALS AND METHODS: Thirty @entity0 entered into the study and were treated preoperatively with @entity7 120 mg/m2 given on day 1 and @entity9 30 mg/m2 given on days 1 and 8, recycled every 3 weeks for a maximum of 3 cycles. The main characteristics of @entity0 were: male/female 23/7, median age 61 years, performance status 0/1/2, 8/17/5. Only @entity0 who achieved an objective response underwent surgery. RESULTS: A total of 82 (91.1%) cycles were administered with moderate @entity2 : WHO grade (G) 2 and 3 @entity10 occurred in 20 (66.6%) @entity0 , G 3 @entity6 occurred in 4 (13.3%), G 3 @entity4 / @entity5 in 20 (66.6%) and G 1-2 @entity1 in 2 (6.6%). Eighteen (60%; exact 95% confidence limits, 40.6% to 77.3%) @entity0 achieved a partial response and 14 (46.6%) underwent surgery. Complete resection (R0) was achieved in 11 (36.6% of all @entity0 ) and pathological complete resection in 5 (16.6%). No @entity3 were reported. The median survival for all @entity0 was 25.5 (exact 95% confidence limits, 13 to 39) months. The median progression-free survival in responsive @entity0 was 27 (exact 95% confidence limits, 13 to 33) months. CONCLUSION: The combination of @entity7 and @entity9 is effective and safe as a neoadjuvant therapy in stage IIIB @entity8 , showing a high response rate (60%) and amenability to surgery.

title: XXXX plus @entity9 as induction chemotherapy followed by surgery in the treatment of stage IIIB @entity8 . Final results of a multicenter phase II study.

answer: @entity7


abstract: BACKGROUND: The combination of @entity7 and @entity9 has been shown to be effective in @entity0 with advanced @entity8 ( @entity8 ). Based on these data, we planned to treat @entity0 with stage IIIB @entity8 without @entity11 and/or metastatic supraclavicular lymph nodes, in order to study the potential effectiveness of this association as neoadjuvant treatment. MATERIALS AND METHODS: Thirty @entity0 entered into the study and were treated preoperatively with @entity7 120 mg/m2 given on day 1 and @entity9 30 mg/m2 given on days 1 and 8, recycled every 3 weeks for a maximum of 3 cycles. The main characteristics of @entity0 were: male/female 23/7, median age 61 years, performance status 0/1/2, 8/17/5. Only @entity0 who achieved an objective response underwent surgery. RESULTS: A total of 82 (91.1%) cycles were administered with moderate @entity2 : WHO grade (G) 2 and 3 @entity10 occurred in 20 (66.6%) @entity0 , G 3 @entity6 occurred in 4 (13.3%), G 3 @entity4 / @entity5 in 20 (66.6%) and G 1-2 @entity1 in 2 (6.6%). Eighteen (60%; exact 95% confidence limits, 40.6% to 77.3%) @entity0 achieved a partial response and 14 (46.6%) underwent surgery. Complete resection (R0) was achieved in 11 (36.6% of all @entity0 ) and pathological complete resection in 5 (16.6%). No @entity3 were reported. The median survival for all @entity0 was 25.5 (exact 95% confidence limits, 13 to 39) months. The median progression-free survival in responsive @entity0 was 27 (exact 95% confidence limits, 13 to 33) months. CONCLUSION: The combination of @entity7 and @entity9 is effective and safe as a neoadjuvant therapy in stage IIIB @entity8 , showing a high response rate (60%) and amenability to surgery.

title: @entity7 plus @entity9 as induction chemotherapy followed by surgery in the treatment of stage IIIB XXXX . Final results of a multicenter phase II study.

answer: @entity8


abstract: BACKGROUND: The combination of @entity7 and @entity9 has been shown to be effective in @entity0 with advanced @entity8 ( @entity8 ). Based on these data, we planned to treat @entity0 with stage IIIB @entity8 without @entity11 and/or metastatic supraclavicular lymph nodes, in order to study the potential effectiveness of this association as neoadjuvant treatment. MATERIALS AND METHODS: Thirty @entity0 entered into the study and were treated preoperatively with @entity7 120 mg/m2 given on day 1 and @entity9 30 mg/m2 given on days 1 and 8, recycled every 3 weeks for a maximum of 3 cycles. The main characteristics of @entity0 were: male/female 23/7, median age 61 years, performance status 0/1/2, 8/17/5. Only @entity0 who achieved an objective response underwent surgery. RESULTS: A total of 82 (91.1%) cycles were administered with moderate @entity2 : WHO grade (G) 2 and 3 @entity10 occurred in 20 (66.6%) @entity0 , G 3 @entity6 occurred in 4 (13.3%), G 3 @entity4 / @entity5 in 20 (66.6%) and G 1-2 @entity1 in 2 (6.6%). Eighteen (60%; exact 95% confidence limits, 40.6% to 77.3%) @entity0 achieved a partial response and 14 (46.6%) underwent surgery. Complete resection (R0) was achieved in 11 (36.6% of all @entity0 ) and pathological complete resection in 5 (16.6%). No @entity3 were reported. The median survival for all @entity0 was 25.5 (exact 95% confidence limits, 13 to 39) months. The median progression-free survival in responsive @entity0 was 27 (exact 95% confidence limits, 13 to 33) months. CONCLUSION: The combination of @entity7 and @entity9 is effective and safe as a neoadjuvant therapy in stage IIIB @entity8 , showing a high response rate (60%) and amenability to surgery.

title: @entity7 plus XXXX as induction chemotherapy followed by surgery in the treatment of stage IIIB @entity8 . Final results of a multicenter phase II study.

answer: @entity9


abstract: @entity7 carrying anhydrous @entity8 ( @entity9 ) fell off a freeway, releasing a dense cloud of @entity9 gas, killing several @entity0 . The driver was dead upon impact. To our knowledge, pulmonary @entity9 @entity4 in @entity0 has not been studied previously by electron microscopy (EM). Therefore, in two cases, the paraffin-embedded tissue blocks of lung were deparaffinized and reembedded in plastic for 1-mu sections and EM examination. The lung tissue of a third case, the truck driver, was similarly processed as a control. Light-microscopic pulmonary findings in the acute @entity9 deaths included denudation of the tracheobronchial epithelium, @entity1 , and marked @entity1 , @entity5 , and @entity6 . In contrast, in the truck driver's lungs, the bronchial epithelium was intact, and there was no gross odor of @entity9 . Massive @entity6 in his lungs were attributed to @entity2 rather than @entity9 inhalation. EM examination of the lungs of the truck driver showed no discernible toxic alterations in either the capillary endothelial cells or the Type I or II alveolar epithelial cells, and alveolar and capillary basement membranes were intact. In contrast, EM study of the lungs from two individuals dying acutely of @entity9 inhalation showed marked swelling and imbitional @entity1 of Type I alveolar epithelial cells; however, @entity3 membranes and capillary endothelial cells appeared as usual. These electron-microscopic findings demonstrate the Type I epithelial cell to be the target cell of acute alveolar wall injury in @entity9 inhalation.

title: Ultrastructure of acute @entity8 XXXX in the @entity0 lung.

answer: @entity4


abstract: @entity7 carrying anhydrous @entity8 ( @entity9 ) fell off a freeway, releasing a dense cloud of @entity9 gas, killing several @entity0 . The driver was dead upon impact. To our knowledge, pulmonary @entity9 @entity4 in @entity0 has not been studied previously by electron microscopy (EM). Therefore, in two cases, the paraffin-embedded tissue blocks of lung were deparaffinized and reembedded in plastic for 1-mu sections and EM examination. The lung tissue of a third case, the truck driver, was similarly processed as a control. Light-microscopic pulmonary findings in the acute @entity9 deaths included denudation of the tracheobronchial epithelium, @entity1 , and marked @entity1 , @entity5 , and @entity6 . In contrast, in the truck driver's lungs, the bronchial epithelium was intact, and there was no gross odor of @entity9 . Massive @entity6 in his lungs were attributed to @entity2 rather than @entity9 inhalation. EM examination of the lungs of the truck driver showed no discernible toxic alterations in either the capillary endothelial cells or the Type I or II alveolar epithelial cells, and alveolar and capillary basement membranes were intact. In contrast, EM study of the lungs from two individuals dying acutely of @entity9 inhalation showed marked swelling and imbitional @entity1 of Type I alveolar epithelial cells; however, @entity3 membranes and capillary endothelial cells appeared as usual. These electron-microscopic findings demonstrate the Type I epithelial cell to be the target cell of acute alveolar wall injury in @entity9 inhalation.

title: Ultrastructure of acute XXXX @entity4 in the @entity0 lung.

answer: @entity8


abstract: @entity7 carrying anhydrous @entity8 ( @entity9 ) fell off a freeway, releasing a dense cloud of @entity9 gas, killing several @entity0 . The driver was dead upon impact. To our knowledge, pulmonary @entity9 @entity4 in @entity0 has not been studied previously by electron microscopy (EM). Therefore, in two cases, the paraffin-embedded tissue blocks of lung were deparaffinized and reembedded in plastic for 1-mu sections and EM examination. The lung tissue of a third case, the truck driver, was similarly processed as a control. Light-microscopic pulmonary findings in the acute @entity9 deaths included denudation of the tracheobronchial epithelium, @entity1 , and marked @entity1 , @entity5 , and @entity6 . In contrast, in the truck driver's lungs, the bronchial epithelium was intact, and there was no gross odor of @entity9 . Massive @entity6 in his lungs were attributed to @entity2 rather than @entity9 inhalation. EM examination of the lungs of the truck driver showed no discernible toxic alterations in either the capillary endothelial cells or the Type I or II alveolar epithelial cells, and alveolar and capillary basement membranes were intact. In contrast, EM study of the lungs from two individuals dying acutely of @entity9 inhalation showed marked swelling and imbitional @entity1 of Type I alveolar epithelial cells; however, @entity3 membranes and capillary endothelial cells appeared as usual. These electron-microscopic findings demonstrate the Type I epithelial cell to be the target cell of acute alveolar wall injury in @entity9 inhalation.

title: Ultrastructure of acute @entity8 @entity4 in the XXXX lung.

answer: @entity0


abstract: UNASSIGNED: @entity4 ( @entity4 ) is a @entity2 with severe economic consequences for @entity3 . Natural hosts for the @entity4 virus (CSFV) are members of the family Suidae, i.e., Eurasian @entity1 ( @entity1 ) are also susceptible. @entity4 in @entity1 poses a serious threat to @entity3 . CSFV is an enveloped RNA virus belonging to the pestivirus genus of the Flaviviridae family. Transmission of the @entity0 is usually by direct contact or by feeding of contaminated meat products. In recent decades @entity4 has been successfully eradicated from Australia, North America, and the European Union. In areas with dense @entity1 populations @entity4 tends to become endemic whereas it is often self-limiting in small, less dense populations. In recent decades eradication strategies of @entity4 in @entity1 have been improved considerably. The reduction of the number of susceptible animals to a threshold level where the basic reproductive number is R 0 < 1 is the major goal of all control efforts. Depending on the epidemiological situation, hunting measures combined with strict hygiene may be effective in areas with a relatively low density of @entity1 . Oral immunization was shown to be highly effective in endemic situations in areas with a high density of @entity1 .

title: The control of classical swine fever in XXXX .

answer: @entity1


abstract: We investigated the process of swallowing disturbance in the @entity0 with @entity1 ( @entity1 ). Swallowing function of 11 @entity0 with @entity1 (67.5 +/- 7.5 y.o.) was evaluated by videofluorography (VF) and swallowing part of @entity1 functional rating scale (FRSsw) more than 2 times during the course. Percent of forced vital capacity (%FVC) was also measured. VF measures were oral leakage, poor bolus formation, retention in oral cavity, abnormal transport to pharynx as oral stage and delayed swallowing reflex, laryngeal penetration, aspiration, nasal regurgitation, retention in valleculae and pyriform, and abnormal opening of pharyngo-esophageal segment as pharyngeal stage. FRSsw were defined as 4: normal eating habits, 3: early eating problems--occasional choking 2: dietary consistency changes, 1: needs supplemental tube feeding and 0:NPO (exclusively parental or enteral feeding). According to VF findings in the course of oral stage and pharyngeal stage, in some @entity0 , the disturbance of oral stage preceded that of pharyngeal stage, while in the other @entity0 , the disturbance of pharyngeal stage disturbance preceded that of oral stage, and in another @entity0 were mixed course. There was poor relationship between the FRSsw and VF measure. Even in the @entity0 of FRSsw 4 _ 3. penetration/aspiration were found. %FVC was 70.0 +/- 17.3% in @entity0 with FRSsw 4 _ 3, 43.1 +/- 17.6% in @entity0 with FRSsw 2 and 40.4 +/- 16.2% in @entity0 with FRS 1 _ 0. In the individual course, FRSsw decreased in parallel with %FVC. We conclude that there are various course of swallowing disturbance on VF findings, the oral stage disturbance proceed, the pharyngeal stage disturbance proceed or mixed. Swallowing function deteriorate in parallel with respiratory function in @entity1 @entity0 . We have to take measures against the @entity2 even in early stage.

title: [Process of swallowing disturbance in XXXX --evaluation of videofluorography and respiratory function].

answer: @entity1


abstract: The effects of fetal pancreatectomy on the uptake of @entity0 , @entity1 and @entity3 by the fetus, uterus and uteroplacental tissues were investigated in chronically catheterized @entity2 during the last third of gestation. Pancreatectomy reduced the uptake of @entity1 by the fetus but had little apparent effect on @entity1 uptake by the uterus or uteroplacental tissues. The mean umbilical uptake of @entity1 by the pancreatectomized fetuses was 10.4 +/- 1.1 mumol/kg . min (n = 4) which was significantly less than the value observed in the intact fetuses (24.5 +/- 2.7 mumol/kg . min, n = 4, P less than 0.01). When all the data from the pancreatectomized and intact fetuses were combined, there was a significant positive correlation between the plasma @entity4 concentration in utero and the umbilical uptake of @entity1 (r = 0.95, n = 14, P less than 0.01). The @entity1 / @entity0 quotient in the pancreatectomized fetuses (0.32 +/- 0.02, n = 9) was significantly less than the value observed in the intact fetuses (0.59 +/- 0.04, n = 6, P less than 0.01). There was also a significant positive correlation between the @entity1 / @entity0 quotient and the plasma concentration of @entity4 in the fetus (r = 0.73, n = 59, P less than 0.01). Pancreatectomy had no significant effect on the fetal @entity3 / @entity0 quotient or on the uptake of @entity0 or @entity3 by any of the tissues. These observations demonstrate that the endogenous concentration of @entity4 is a physiological regulator of @entity1 uptake by the fetal tissues.

title: The effect of pancreatectomy on the uptake of metabolites by the XXXX fetus.

answer: @entity2


abstract: UNASSIGNED: Cryotherapy (or cold treatment) has been a popular treatment to relieve @entity2 caused by injuries to tissues such as tendons. However, the exact mechanisms behind the beneficial effects of cryotherapy in tendons remain largely unclear. As @entity4 ( @entity4 ) is known to be a major mediator of acute @entity1 in tissues, which is related to tissue @entity2 , we hypothesized that the beneficial effects of cryotherapy in tendons are mediated by downregulation of @entity4 levels. To test this hypothesis, we applied cold treatment to @entity0 @entity3 using two animal models: exhaustive @entity0 treadmill running and acute @entity0 @entity5 by needle penetration. We then measured the levels of @entity4 and protein expression levels of @entity6 , an enzyme responsible for @entity4 production in tissues, under both experimental conditions. We found that treadmill running increased @entity4 levels in both @entity3 compared to control @entity0 without running. Cold treatment for 30 min after treadmill running was sufficient to reduce @entity4 levels to near baseline control levels in both tendons. An extension of cold treatment to 60 min resulted only in a marginal @entity3 , but a marked @entity3 . Moreover, @entity6 protein levels in both tendons were also lowered by cold treatment, suggesting that the reduction of @entity4 levels in tendons by cold treatment is at least in part due to the decreased @entity6 expression. Similarly, in the acutely injured tendons, 30 min of cold treatment after needle penetration reduced @entity4 levels when compared to the controls at room temperature (22  C). This decrease was sustained up to at least 3 h after the administration of cryotherapy. Given that @entity4 is a known @entity2 sensitiser, the results of this study suggest that the ability of cold treatment to reduce @entity2 may be attributable to its ability to decrease @entity4 production in tendons.

title: Cryotherapy suppresses XXXX in an animal model.

answer: @entity1


abstract: @entity0 with @entity2 (n = 22), @entity3 (n = 5), inactive @entity6 (n = 1), @entity7 (n = 2), @entity4 (n = 1) and @entity8 (n = 2) were examined with 111In- @entity9 labelled "mixed" leukocyte preparations (n = 12) or with @entity10 labelled "pure" granulocyte preparations (n = 21). Compared with barium enemas of the gut and colonoscopy, performed within of one week in 31 @entity0 there was a correct location of infiltrated bowel segments in 24 @entity0 (78%). The scan diagnosed more infiltrated segments in 4 @entity0 (13%). In 3 @entity0 it failed to diagnose one inflamed segment. In 24 @entity0 the faecal 111In-excretion was expressed as percentage of the reinjected 111In-activity. All @entity0 with non @entity1 and @entity0 with inactive @entity1 excreted less than 2% of the reinjected 111In-activity. All but one female @entity0 with active @entity1 excreted more than 2%. In 24 @entity0 the correlation of ESR, CDAI and A.I. was available. There was a good correlation between ESR (r = 0.77, P less than 0.001), A.I. (r = 0.61, p less than 0.001) and the %-faecal @entity5 . The 111In-labelling of white blood cells, especially of granulocytes, seems to be a reliable alternative method to localize infiltrated bowel segments and to assess disease activity in @entity0 with @entity1 , compared to usually performed radiological, endoscopical and clinical methods.

title: [ XXXX marked leukocytes: a method for diagnosing the location and evaluating the activity of @entity2 and @entity3 ].

answer: @entity10


abstract: @entity0 with @entity2 (n = 22), @entity3 (n = 5), inactive @entity6 (n = 1), @entity7 (n = 2), @entity4 (n = 1) and @entity8 (n = 2) were examined with 111In- @entity9 labelled "mixed" leukocyte preparations (n = 12) or with @entity10 labelled "pure" granulocyte preparations (n = 21). Compared with barium enemas of the gut and colonoscopy, performed within of one week in 31 @entity0 there was a correct location of infiltrated bowel segments in 24 @entity0 (78%). The scan diagnosed more infiltrated segments in 4 @entity0 (13%). In 3 @entity0 it failed to diagnose one inflamed segment. In 24 @entity0 the faecal 111In-excretion was expressed as percentage of the reinjected 111In-activity. All @entity0 with non @entity1 and @entity0 with inactive @entity1 excreted less than 2% of the reinjected 111In-activity. All but one female @entity0 with active @entity1 excreted more than 2%. In 24 @entity0 the correlation of ESR, CDAI and A.I. was available. There was a good correlation between ESR (r = 0.77, P less than 0.001), A.I. (r = 0.61, p less than 0.001) and the %-faecal @entity5 . The 111In-labelling of white blood cells, especially of granulocytes, seems to be a reliable alternative method to localize infiltrated bowel segments and to assess disease activity in @entity0 with @entity1 , compared to usually performed radiological, endoscopical and clinical methods.

title: [ @entity10 marked leukocytes: a method for diagnosing the location and evaluating the activity of XXXX and @entity3 ].

answer: @entity2


abstract: @entity0 with @entity2 (n = 22), @entity3 (n = 5), inactive @entity6 (n = 1), @entity7 (n = 2), @entity4 (n = 1) and @entity8 (n = 2) were examined with 111In- @entity9 labelled "mixed" leukocyte preparations (n = 12) or with @entity10 labelled "pure" granulocyte preparations (n = 21). Compared with barium enemas of the gut and colonoscopy, performed within of one week in 31 @entity0 there was a correct location of infiltrated bowel segments in 24 @entity0 (78%). The scan diagnosed more infiltrated segments in 4 @entity0 (13%). In 3 @entity0 it failed to diagnose one inflamed segment. In 24 @entity0 the faecal 111In-excretion was expressed as percentage of the reinjected 111In-activity. All @entity0 with non @entity1 and @entity0 with inactive @entity1 excreted less than 2% of the reinjected 111In-activity. All but one female @entity0 with active @entity1 excreted more than 2%. In 24 @entity0 the correlation of ESR, CDAI and A.I. was available. There was a good correlation between ESR (r = 0.77, P less than 0.001), A.I. (r = 0.61, p less than 0.001) and the %-faecal @entity5 . The 111In-labelling of white blood cells, especially of granulocytes, seems to be a reliable alternative method to localize infiltrated bowel segments and to assess disease activity in @entity0 with @entity1 , compared to usually performed radiological, endoscopical and clinical methods.

title: [ @entity10 marked leukocytes: a method for diagnosing the location and evaluating the activity of @entity2 and XXXX ].

answer: @entity3


abstract: @entity4 @entity1 were immunized with @entity2 retina and complete Freund's adjuvant by the intradermal route. Blood was obtained by complete bleeding of the @entity1 and stored at -20 degrees C. Their eyes were enucleated and submitted to histopathological techniques. Humoral antiretinal antibodies were detected by Ouchterlony, immunoelectrophoresis and crossed-immunoelectrophoresis, yielding precipitins presumably of the IgG type. Sensitized lymphocytes were also detected by their incubation with the retinal extract and the soluble fractions belonging to the peaks no 1 and no 2 ("S antigen") in the @entity5 and TTL techniques. The whole extract was passed through a Sephadex G 100 and DEAE cellulose columns and several soluble fractions were obtained. Two major protein peaks were detected (no 1 and no 2) that were subdivided into five other protein peaks (1A, 1B, 2A, 2B and 2C). Sugars were not present and molecular weights were 50,000 daltons for peak no 2 and higher than 66.000 for peak no 1. The whole protein content of the extract and of the different soluble fractions were established by the Lowry method. Histopathological studies revealed extensive lesions of the uveal tract consisting of a cellular infiltrate rich in lymphocytes and monocytes. Increased vascularization of retina was also appreciated. This experimental model represents a guide in the approach to the @entity0 @entity3 of unknown origin whose immunological findings will be presented in a forthcoming issue.

title: [Autoimmune uveitis. I. Immunochemical properties of the soluble fractions of XXXX retina].

answer: @entity2


abstract: Twenty-two @entity0 underwent aortic valve replacement for @entity2 with a preoperative ejection fraction less than 45%. Three @entity0 died peroperatively and a fourth @entity0 died 18 months later before the haemodynamic control. The other 18 @entity0 were systematically reinvestigated, on average 16 months after surgery. Sixteen had a remarkable functional improvement and a significant increase in ejection fraction at haemodynamic control: 32 +/- 6% to 61 +/- 8%, p less than 0.001. They were surgical successes (Group I). In this group, the 7 @entity0 with the most severe alteration of ventricular function and an average ejection fraction of: 26 +/- 3%, also improved to near normal function with a postoperative fraction of 62 +/- 11%. There was no significant improvement of the ejection fraction in 2 @entity0 , and they were classified with the fatalities as @entity1 (Group II). The clinical, electrocardiographic, radiological, haemodynamic and angiographic data of these two populations were compared to try and identify preoperative indices of prognostic value. Only the angiographic left ventricular myocardial mass index (LVMI) was significantly higher in Group II (253 +/- 98 g/m2) than in Group I (156 +/- 56 g/m2, p less than 0.05). A discriminating analysis showed that the most important parameters to separate the 2 groups of @entity0 were the LVMI and the thickness of the left ventricular wall. The marked increase of the postoperative ejection fraction in 3/4 of our @entity0 confirmed the clinical value of valvular replacement justifying the indication for surgery in @entity0 with severe @entity2 in spite of a severe alteration of left ventricular function.

title: [ XXXX with low preoperative ejection fraction. Long-term postoperative hemodynamic and angiographic studies].

answer: @entity2


abstract: Twenty-five @entity0 with @entity2 confirmed by clinical, echocardiographic and haemodynamic investigations were treated with high dose @entity3 (320 to 800 mg/day, average 420 mg/day) and assessed after an average follow-up period of 25 months. The effects of treatment were assessed by interrogation in all @entity0 and by exercise testing before and after @entity3 in 19 cases. Comparative echocardiographic (21 @entity0 ) Holter (20 @entity0 ) and catheter studies (14 @entity0 ) were also performed. The cardiovascular mortality rate during the study period was nil. All @entity0 were symptomatic before treatment; 9 became asymptomatic and 13 @entity0 were improved, the average functional score decreasing from 5.16 +/- 2.15 to 2.28 +/- 1.49 (p less than 0.001). The persistence of severe symptoms led to withdrawal of the beta-blocker in 2 cases. There was a parallel improvement in maximal work capacity during exercise stress testing (96 +/- 27 watts vs 117 +/- 30 watts, p less than 0.01). A resting intraventricular pressure gradient was recorded in 12 of the 14 @entity0 undergoing repeat catheter study which decreased after @entity3 from an average of 66.75 +/- 32.72 mmHg to 42.75 +/- 37.6 mmHg (p less than 0.05). Left ventricular end diastolic pressures remained unchanged. The change in pressure gradient did not correlate with the symptomatology and there were no associated echocardiographic changes. The Holter monitoring did not show any improvement of ventricular hyperexcitability under @entity3 : the number of @entity0 with complex @entity1 remained unchanged (7 @entity0 ).(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Outcome of XXXX treated with high doses of @entity3 ].

answer: @entity2


abstract: Twenty-five @entity0 with @entity2 confirmed by clinical, echocardiographic and haemodynamic investigations were treated with high dose @entity3 (320 to 800 mg/day, average 420 mg/day) and assessed after an average follow-up period of 25 months. The effects of treatment were assessed by interrogation in all @entity0 and by exercise testing before and after @entity3 in 19 cases. Comparative echocardiographic (21 @entity0 ) Holter (20 @entity0 ) and catheter studies (14 @entity0 ) were also performed. The cardiovascular mortality rate during the study period was nil. All @entity0 were symptomatic before treatment; 9 became asymptomatic and 13 @entity0 were improved, the average functional score decreasing from 5.16 +/- 2.15 to 2.28 +/- 1.49 (p less than 0.001). The persistence of severe symptoms led to withdrawal of the beta-blocker in 2 cases. There was a parallel improvement in maximal work capacity during exercise stress testing (96 +/- 27 watts vs 117 +/- 30 watts, p less than 0.01). A resting intraventricular pressure gradient was recorded in 12 of the 14 @entity0 undergoing repeat catheter study which decreased after @entity3 from an average of 66.75 +/- 32.72 mmHg to 42.75 +/- 37.6 mmHg (p less than 0.05). Left ventricular end diastolic pressures remained unchanged. The change in pressure gradient did not correlate with the symptomatology and there were no associated echocardiographic changes. The Holter monitoring did not show any improvement of ventricular hyperexcitability under @entity3 : the number of @entity0 with complex @entity1 remained unchanged (7 @entity0 ).(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Outcome of @entity2 treated with high doses of XXXX ].

answer: @entity3


abstract: BACKGROUND: This study was conducted to establish the minimal detectable change (MDC) and @entity2 ( @entity2 ) of the physical category of the @entity1 -Specific Quality of Life Scale in @entity0 with @entity1 . METHODS: MDC and @entity2 scores were calculated from the data of 74 @entity0 enrolled in randomized controlled trials investigating the effects of two rehabilitation programs in @entity0 with @entity1 . These @entity0 received treatments for 3 weeks and underwent clinical assessment before and after treatment. To obtain test-retest reliability for calculating MDC, another 25 @entity0 with @entity1 were recruited. The MDC was calculated from the standard error of measurement (SEM) to indicate a real change with 95% confidence for individual @entity0 (MDC95). Distribution-based and anchor-based methods were adopted to triangulate the ranges of minimal @entity2 . The percentage of scale width was calculated by dividing the MDC and @entity2 by the total score range of each physical category. The percentage of @entity0 exceeding MDC95 and minimal @entity2 was also reported. RESULTS: The MDC95 of the mobility, self-care, and @entity3 ( @entity3 ) function subscales were 5.9, 4.0, and 5.3 respectively. The minimal CID ranges for these 3 subscales were 1.5 to 2.4, 1.2 to 1.9, and 1.2 to 1.8. The percentage of @entity0 exceeding MDC95 and minimal @entity2 of the mobility, self-care, and @entity3 function subscales were 9.5% to 28.4%, 6.8% to 28.4%, and 12.2% to 33.8%, respectively. CONCLUSIONS: The change score of an individual @entity0 has to reach 5.9, 4.0, and 5.3 on the 3 subscales to indicate a true change. The mean change scores of a group of @entity0 with @entity1 on these subscales should reach the lower bound of CID ranges of 1.5 (6.3% scale width), 1.2 (6.0% scale width), and 1.2 (6.0% scale width) to be regarded as clinically important change. This information may facilitate interpretations of @entity0 -reported outcomes after @entity1 rehabilitation. Future research is warranted to validate these findings.

title: Assessing the @entity1 -specific quality of life for outcome measurement in XXXX rehabilitation: minimal detectable change and clinically important difference.

answer: @entity1


abstract: BACKGROUND: This study was conducted to establish the minimal detectable change (MDC) and @entity2 ( @entity2 ) of the physical category of the @entity1 -Specific Quality of Life Scale in @entity0 with @entity1 . METHODS: MDC and @entity2 scores were calculated from the data of 74 @entity0 enrolled in randomized controlled trials investigating the effects of two rehabilitation programs in @entity0 with @entity1 . These @entity0 received treatments for 3 weeks and underwent clinical assessment before and after treatment. To obtain test-retest reliability for calculating MDC, another 25 @entity0 with @entity1 were recruited. The MDC was calculated from the standard error of measurement (SEM) to indicate a real change with 95% confidence for individual @entity0 (MDC95). Distribution-based and anchor-based methods were adopted to triangulate the ranges of minimal @entity2 . The percentage of scale width was calculated by dividing the MDC and @entity2 by the total score range of each physical category. The percentage of @entity0 exceeding MDC95 and minimal @entity2 was also reported. RESULTS: The MDC95 of the mobility, self-care, and @entity3 ( @entity3 ) function subscales were 5.9, 4.0, and 5.3 respectively. The minimal CID ranges for these 3 subscales were 1.5 to 2.4, 1.2 to 1.9, and 1.2 to 1.8. The percentage of @entity0 exceeding MDC95 and minimal @entity2 of the mobility, self-care, and @entity3 function subscales were 9.5% to 28.4%, 6.8% to 28.4%, and 12.2% to 33.8%, respectively. CONCLUSIONS: The change score of an individual @entity0 has to reach 5.9, 4.0, and 5.3 on the 3 subscales to indicate a true change. The mean change scores of a group of @entity0 with @entity1 on these subscales should reach the lower bound of CID ranges of 1.5 (6.3% scale width), 1.2 (6.0% scale width), and 1.2 (6.0% scale width) to be regarded as clinically important change. This information may facilitate interpretations of @entity0 -reported outcomes after @entity1 rehabilitation. Future research is warranted to validate these findings.

title: Assessing the XXXX -specific quality of life for outcome measurement in @entity1 rehabilitation: minimal detectable change and clinically important difference.

answer: @entity1


abstract: BACKGROUND: Lipoprotein-associated phospholipase A    (Lp- @entity5   ) is a recently identified and potentially useful plasma biomarker for cardiovascular and @entity3 . However, the correlation between the Lp- @entity5    activity and @entity6 remains poorly investigated in @entity0 with @entity2 ( @entity2 ). The present study aimed to evaluate the potential role of Lp- @entity5    as a comprehensive marker of @entity2 in individuals with and without @entity6 . METHODS: We documented 118 consecutive @entity0 with @entity2 and 70 age- and sex-matched healthy subjects served as controls. The @entity0 were further divided into two groups: 39 with carotid plaques and 79 without carotid plaques to elucidate the influence of Lp- @entity5    on @entity6 . The plasma Lp- @entity5    activity was measured by using ELISA method and carotid @entity4 ( @entity4 ) was performed by ultrasound in all @entity0 . RESULTS: Lp- @entity5    activity was significantly increased in @entity2 subgroups when compared with controls, and was higher in @entity0 with carotid plaques than those without plaques (P < 0.05). Furthermore, we found that significant difference in Lp- @entity5    was obtained between @entity0 with three and four disorders of @entity2 (P < 0.01). Age (b = 0.183, P = 0.029), LDL- @entity1 (b = 0.401, P = 0.000) and waist-hip ratio (b = 0.410, P = 0.000) emerged as significant and independent determinants of Lp- @entity5    activity. Multiple stepwise regression analysis revealed that LDL- @entity1 (b = 0.309, P = 0.000), systolic blood pressure (b = 0.322, P = 0.002) and age (b = 0.235, P = 0.007) significantly correlated with max @entity4 , and @entity7 was not an independent predictor for @entity4 . CONCLUSIONS: Lp- @entity5    may be a modulating factor for @entity4 via age and LDL- @entity1 , not independent predictor in the pathophysiological process of @entity6 in @entity0 with @entity2 .

title: Plasma lipoprotein-associated phospholipase A2 in @entity0 with @entity2 and XXXX .

answer: @entity6


abstract: BACKGROUND: Lipoprotein-associated phospholipase A    (Lp- @entity5   ) is a recently identified and potentially useful plasma biomarker for cardiovascular and @entity3 . However, the correlation between the Lp- @entity5    activity and @entity6 remains poorly investigated in @entity0 with @entity2 ( @entity2 ). The present study aimed to evaluate the potential role of Lp- @entity5    as a comprehensive marker of @entity2 in individuals with and without @entity6 . METHODS: We documented 118 consecutive @entity0 with @entity2 and 70 age- and sex-matched healthy subjects served as controls. The @entity0 were further divided into two groups: 39 with carotid plaques and 79 without carotid plaques to elucidate the influence of Lp- @entity5    on @entity6 . The plasma Lp- @entity5    activity was measured by using ELISA method and carotid @entity4 ( @entity4 ) was performed by ultrasound in all @entity0 . RESULTS: Lp- @entity5    activity was significantly increased in @entity2 subgroups when compared with controls, and was higher in @entity0 with carotid plaques than those without plaques (P < 0.05). Furthermore, we found that significant difference in Lp- @entity5    was obtained between @entity0 with three and four disorders of @entity2 (P < 0.01). Age (b = 0.183, P = 0.029), LDL- @entity1 (b = 0.401, P = 0.000) and waist-hip ratio (b = 0.410, P = 0.000) emerged as significant and independent determinants of Lp- @entity5    activity. Multiple stepwise regression analysis revealed that LDL- @entity1 (b = 0.309, P = 0.000), systolic blood pressure (b = 0.322, P = 0.002) and age (b = 0.235, P = 0.007) significantly correlated with max @entity4 , and @entity7 was not an independent predictor for @entity4 . CONCLUSIONS: Lp- @entity5    may be a modulating factor for @entity4 via age and LDL- @entity1 , not independent predictor in the pathophysiological process of @entity6 in @entity0 with @entity2 .

title: Plasma lipoprotein-associated phospholipase A2 in @entity0 with XXXX and @entity6 .

answer: @entity2


abstract: BACKGROUND: Lipoprotein-associated phospholipase A    (Lp- @entity5   ) is a recently identified and potentially useful plasma biomarker for cardiovascular and @entity3 . However, the correlation between the Lp- @entity5    activity and @entity6 remains poorly investigated in @entity0 with @entity2 ( @entity2 ). The present study aimed to evaluate the potential role of Lp- @entity5    as a comprehensive marker of @entity2 in individuals with and without @entity6 . METHODS: We documented 118 consecutive @entity0 with @entity2 and 70 age- and sex-matched healthy subjects served as controls. The @entity0 were further divided into two groups: 39 with carotid plaques and 79 without carotid plaques to elucidate the influence of Lp- @entity5    on @entity6 . The plasma Lp- @entity5    activity was measured by using ELISA method and carotid @entity4 ( @entity4 ) was performed by ultrasound in all @entity0 . RESULTS: Lp- @entity5    activity was significantly increased in @entity2 subgroups when compared with controls, and was higher in @entity0 with carotid plaques than those without plaques (P < 0.05). Furthermore, we found that significant difference in Lp- @entity5    was obtained between @entity0 with three and four disorders of @entity2 (P < 0.01). Age (b = 0.183, P = 0.029), LDL- @entity1 (b = 0.401, P = 0.000) and waist-hip ratio (b = 0.410, P = 0.000) emerged as significant and independent determinants of Lp- @entity5    activity. Multiple stepwise regression analysis revealed that LDL- @entity1 (b = 0.309, P = 0.000), systolic blood pressure (b = 0.322, P = 0.002) and age (b = 0.235, P = 0.007) significantly correlated with max @entity4 , and @entity7 was not an independent predictor for @entity4 . CONCLUSIONS: Lp- @entity5    may be a modulating factor for @entity4 via age and LDL- @entity1 , not independent predictor in the pathophysiological process of @entity6 in @entity0 with @entity2 .

title: Plasma lipoprotein-associated phospholipase A2 in XXXX with @entity2 and @entity6 .

answer: @entity0


abstract: Abnormal Wnt signaling and impaired cell-cell adhesion due to abnormal @entity7 and @entity6 function have been implicated in many @entity2 , but have not been fully explored in @entity3 . The aim of this study was to analyze @entity6 cellular location and @entity7 expression levels in @entity3 . @entity7 expression levels were also correlated with clinical data and underlying pathology. @entity6 and @entity7 expression were examined in 18 @entity3 and 7 non-tumoral inflammatory pharynx tissues using immunohistochemical methods. @entity0 clinical data were collected, and histological evaluation was performed by @entity4 / @entity5 staining. @entity6 was detected in membrane and cytoplasm in all cases of @entity3 , regardless of histological type; in non-tumoral tissues, however, @entity6 was observed only in the membrane. As for @entity7 expression levels, strong staining was observed in most non-tumoral tissues, but staining was only moderate in @entity3 tissues. @entity7 expression was associated with @entity6 localization, study group, @entity1 , and @entity0 outcomes. Reduced levels of @entity7 protein observed in nasopharyngeal carinoma may play an important role in invasion and @entity1 . Cytoplasmic @entity6 in @entity3 may impair cell-cell adhesion, promoting invasive behavior and a @entity1 phenotype.

title: The cadherin-catenin complex in XXXX .

answer: @entity3


abstract: Eighteen @entity0 with sustained @entity2 underwent serial electrophysiological studies to establish the therapeutic efficacy of @entity4 as compared to other available anti-arrhythmic agents. One or more acutely effective drug was found in 14 of the 18 @entity0 (78%). @entity4 was tested in all 18 @entity0 and was effective in 12 of them (67%). For assessment of the prophylactic efficacy of other anti-arrhythmic agents, an average of 3.5 additional studies per @entity0 were performed resulting in successful prevention of @entity2 in a total of 10 of 63 (16%) additional trials. Nine @entity0 were placed on chronic oral therapy with @entity4 . In these nine @entity0 long-term prophylaxis against @entity2 was documented over a mean follow-up period of 9.6 months (range 2-18 months). The study suggests that @entity4 can provide effective prophylaxis against @entity2 in a significant proportion of @entity0 refractory to other available drugs and that this prophylactic efficacy is predominantly due to its Class III anti-arrhythmic properties. Experimental studies were performed in eight conscious @entity1 3-7 days following proximal LAD ligation. Epicardial recordings were obtained using implanted composite electrodes. @entity4 prevented sustained VT by a predominant increase in refractoriness of the infarcted zone. In vitro, @entity4 caused a significant prolongation of the action potential of @entity3 . Refractoriness of epicardial ventricular fibres was significantly more prolonged in ischemically damaged cells as compared to normal fibres.

title: Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of XXXX .

answer: @entity4


abstract: This report concerns 30 @entity0 with the acute form of " @entity2 " of the aorta treated during a 27-year period between April 1957 and March 1984. There were 28 @entity0 and two @entity0 whose ages ranged from 46 to 78 years (most over 60 years). All were heavy smokers. The @entity2 was located below the renal arteries and the inflammatory changes were limited to the abdomen in 24 @entity0 ; one @entity0 had a @entity5 . The @entity2 involved the entire abdominal aorta in one, the descending thoracic and infrarenal abdominal aorta in two, and the descending thoracic and abdominal aorta in continuity in three @entity0 . The inflammatory changes occurred grossly and microscopically in both abdominal and thoracic aortic segments in five of the latter six @entity0 . The changes were manifested by anterior and lateral mural inflammatory thickening contiguous with similar changes of the retroperitoneum and mediastinum that produced varying degrees of @entity4 in seven @entity0 . Most had @entity3 and abdominal tenderness, suggesting @entity1 . Emergency exploratory operation had been performed elsewhere in 10 @entity0 . Operation was abandoned because of exposure difficulties, bowel perforation, or visceral arterial involvement. Diagnosis was suggested by CT scan in 10, ultrasonography in one, and excretory urograms in seven @entity0 . Treatment consisted of thoracoabdominal aortic replacement in six and infrarenal aortic replacement in 24. The aorta was clamped at the diaphragm in most of the latter cases to avoid injury to adjacent structures. Nephrectomy or ureterolysis was rarely necessary. Of these 30 @entity0 , 29 were early (30 day) survivors and @entity4 spontaneously subsided in most cases without special treatment. There was one late death at 2 months and eight deaths from 3 to 13 years; 20 (67%) @entity0 are still alive.

title: Inflammatory XXXX of the aorta.

answer: @entity2


abstract: Effects of prolonged administration of compound 48/80 (48/80) on the gastric mucosa, @entity2 and @entity1 levels in serum, and mast cells of @entity0 were studied. Daily administration of 48/80 (0.75 mg/kg, i.p.) for 2 or 4 days produced widespread @entity3 . Further administration of the agent for up to 12 days did not aggravate the lesions which had developed in the early period of administration of the drug. There were only a few visible lesions and numerous healed ones. Almost the same phenomenon was observed with the daily administration of @entity2 plus @entity1 (10 mg/kg each, i.p.) for 2 to 12 days. While 48/80 given for 2 or 4 days increased @entity2 and @entity1 levels in serum, it induced no appreciable increase of these @entity4 after 8 or 12 days of treatment. @entity2 and @entity1 levels in peritoneal mast cells significantly decreased after the treatment with 48/80 over a 4 day period. The decrease in @entity3 after prolonged treatment with 48/80 is due to both the depletion of @entity2 and @entity1 from mast cells and an increased resistance of the gastric mucosa with healed lesions.

title: Effects of prolonged treatment with compound 48/80 on the gastric mucosa and mast cells in the XXXX .

answer: @entity0


abstract: A strain of @entity7 isolated from the feces of a @entity0 with @entity5 was examined for growth kinetics and toxic exoproduct formation using the complete (BHI) and synthetic culture media. It was found that the test organism in synthetic medium grew distinctly slower than in BHI. Fractionations on Sephadex G-100 column yielded 3 fractions from the complete medium culture filtrate and 2 fractions from the culture filtrate obtained from synthetic medium. The first culture filtrate fractions (F1) were represented by components of the molecular weight over 100,000, the respective second fractions (F2) from complete and synthetic medium were of the molecular weights of about 40,000 and 10,000. In the early skin test on @entity3 the @entity4 of culture filtrates and their fractions manifested itself by an increased permeability of blood vessels, in the late skin test by a hemorrhagic reaction associated with dilatation of blood vessels and induration of the skin tissue. In a test on @entity2 foot pad all separated filtrate fractions gave a positive @entity1 reaction. In cultured Vero cells samples of synthetic medium fractions gave a distinct cytotoxic reaction. Immunochemically, the presence of @entity6 in culture filtrates as well as some variations in the antigenicity of components from the complete and synthetic medium fractions were found. Apart from @entity6 some additional high-molecular-weight components were also present in the toxic complex of both first filtrate fractions (F1). Much more attention should be given to analysis of these first fraction complexes as well as to toxinogenicity of second fractions (F2) using some additional tests.

title: Toxic exoproducts of XXXX .

answer: @entity7


abstract: We report eyelid margin changes in 3 @entity1 after @entity3 treatment for @entity0 . These @entity1 were referred to Cincinnati Eye Institute for eyelash @entity7 and all had been treated with @entity3 in the near past. The @entity8 started soon after chemotherapy. All 3 cases showed varying degrees of @entity2 and cicatricial changes leading to marginal entropion. The first @entity1 exhibited very prominent eyelid margin @entity2 and diffuse @entity6 without madarosis. The second @entity1 had extensive madarosis and abnormally curved, thin eyelashes with punctal and @entity5 . Her marginal entropion was most prominent at the medial lower eyelids. The last @entity1 showed significant lash misdirection in a scattered distribution and patchy madarosis along with pseudomembranes blocking the puncta. All of these @entity4 occurred soon after @entity3 treatment for @entity0 . Such changes in the absence of questioning for previous @entity3 use in history taking.

title: Cicatricial entropion following XXXX (Taxotere) therapy.

answer: @entity3


abstract: This study examined interactions between @entity3 ( @entity5 ) and angiotensin II (ANG II) in controlling @entity0 ( @entity0 ) and glomerular filtration rate (GFR). In six normal @entity2 , intrarenal @entity5 infusion (1.0 mumol/min) transiently decreased @entity0 , but during sustained @entity5 infusion @entity0 increased to 122 +/- 7% of control, although GFR remained at 75 +/- 6% of control. Blockade of ANG II formation with the converting enzyme inhibitor SQ 14225 (n = 6) almost abolished the transient decrease in @entity0 but did not prevent the sustained fall in GFR caused by @entity5 . When circulating ANG II was held constant by intravenous infusion of SQ 14225 and 20 ng . kg-1 . min-1 of ANG II (n = 6), @entity5 transiently decreased @entity0 but the return of @entity0 was much slower than in normal @entity2 and @entity0 did not increase above control. Maintenance of constant circulating ANG II did not prevent @entity5 -mediated decreases in GFR. These observations suggest that @entity5 -mediated reductions in GFR do not depend entirely on ANG II and may be due to dilation of efferent arterioles by @entity5 . However, the transient renal vasoconstriction caused by @entity5 depends on ANG II, and data from this study suggest that part of the waning constrictor response to @entity5 is due to suppression of @entity4 secretion and endogenous ANG II formation. In circumstances where high ANG II levels are maintained (i.e., @entity1 ), @entity5 may be capable of causing sustained renal vasoconstriction.

title: Interactions between XXXX and angiotensin II in controlling glomerular filtration.

answer: @entity3


abstract: OBJECTIVES: To assess the concomitant clinical improvement in incomplete @entity3 @entity0 (SCIPs) suffering from @entity4 ( @entity4 ), neurogenic lower urinary tract symptoms (NLUTSs) and @entity2 ( @entity2 ) using sacral neuromodulation (SNM) for @entity4 and NLUTSs. METHODS: Seventy-five SCIPs were selected. Before and during the follow-ups post-SNM, NLUTSs and @entity4 were detected mainly through specific diaries. Erectile function was assessed using the International Index of Erectile Function composed of 5 questions (IIEF5). Quality of life (QoL) was measured with the Short Form 36 Health Survey questionnaire (SF-36). During the first stage, in which a permanent electrode was inserted percutaneously into the third sacral foramina and stimulated using an external generator, @entity0 with @entity4 or NLUTSs were required to improve their symptoms by at least 50% compared with baseline before proceeding to the second stage in which the generator was placed in the @entity0 's buttock. @entity2 @entity0 needed to increase their IIEF5 score by at least 25% compared with baseline (evaluated initially 3 months after the second stage) in order to continue follow-up. RESULTS: Fourteen out of 37 subjects who manifested two functional pelvic dysfunctions at baseline maintained notable clinical improvement in two pelvic functions (median follow-up >3 years). Six had non-obstructive retention (NOR) and @entity2 , six double @entity1 , and two constipation with NOR. In the general and mental health domains of the SF-36, all @entity0 improved their scores by at least 20% compared with baseline. CONCLUSIONS: SNM may be beneficial to selected incomplete @entity5 with concomitant pelvic functional disturbances.

title: Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in @entity0 with incomplete XXXX .

answer: @entity3


abstract: OBJECTIVES: To assess the concomitant clinical improvement in incomplete @entity3 @entity0 (SCIPs) suffering from @entity4 ( @entity4 ), neurogenic lower urinary tract symptoms (NLUTSs) and @entity2 ( @entity2 ) using sacral neuromodulation (SNM) for @entity4 and NLUTSs. METHODS: Seventy-five SCIPs were selected. Before and during the follow-ups post-SNM, NLUTSs and @entity4 were detected mainly through specific diaries. Erectile function was assessed using the International Index of Erectile Function composed of 5 questions (IIEF5). Quality of life (QoL) was measured with the Short Form 36 Health Survey questionnaire (SF-36). During the first stage, in which a permanent electrode was inserted percutaneously into the third sacral foramina and stimulated using an external generator, @entity0 with @entity4 or NLUTSs were required to improve their symptoms by at least 50% compared with baseline before proceeding to the second stage in which the generator was placed in the @entity0 's buttock. @entity2 @entity0 needed to increase their IIEF5 score by at least 25% compared with baseline (evaluated initially 3 months after the second stage) in order to continue follow-up. RESULTS: Fourteen out of 37 subjects who manifested two functional pelvic dysfunctions at baseline maintained notable clinical improvement in two pelvic functions (median follow-up >3 years). Six had non-obstructive retention (NOR) and @entity2 , six double @entity1 , and two constipation with NOR. In the general and mental health domains of the SF-36, all @entity0 improved their scores by at least 20% compared with baseline. CONCLUSIONS: SNM may be beneficial to selected incomplete @entity5 with concomitant pelvic functional disturbances.

title: Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in XXXX with incomplete @entity3 .

answer: @entity0


abstract: A versatile strategy to endow dental implants with long-term antibacterial ability without compromising the cytocompatibility is highly desirable to combat implant-related @entity2 . @entity3 nanoparticles (Ag NPs) have been utilized as a highly effective and broad-spectrum antibacterial agent for surface modification of biomedical devices. However, the high mobility and subsequent hazardous effects of the particles on @entity0 cells may limit its practical applications. Thus, Ag NPs were immobilized on the surface of sand-blasted, large grit, and acid-etched (SLA) @entity4 by manipulating the @entity6 heating effect of @entity3 plasma immersion ion implantation. The @entity3 plasma immersion ion implantation-treated SLA surface gave rise to both good antibacterial activity and excellent compatibility with @entity0 cells. The antibacterial activity rendered by the immobilized Ag NPs was assessed using @entity7 and @entity5 , commonly suspected pathogens for peri-implant disease. The immobilized Ag NPs offered a good defense against multiple cycles of bacteria attack in both @entity7 and @entity5 , and the mechanism was independent of @entity3 release. @entity7 showed a higher susceptibility to Ag NPs than @entity5 , which might be explained by the presence of different wall structures. Moreover, the immobilized Ag NPs had no apparent toxic influence on the viability, proliferation, and differentiation of @entity1 bone marrow mesenchymal stem cells. These results demonstrated that good bactericidal activity could be obtained with very small quantities of immobilized Ag NPs, which were not detrimental to the @entity0 cells involved in the osseointegration process, and promising for @entity4 -based dental implants with commercial SLA surfaces.

title: Hierarchical micro/nanostructured XXXX with balanced actions to bacterial and @entity0 cells for dental implants.

answer: @entity4


abstract: A versatile strategy to endow dental implants with long-term antibacterial ability without compromising the cytocompatibility is highly desirable to combat implant-related @entity2 . @entity3 nanoparticles (Ag NPs) have been utilized as a highly effective and broad-spectrum antibacterial agent for surface modification of biomedical devices. However, the high mobility and subsequent hazardous effects of the particles on @entity0 cells may limit its practical applications. Thus, Ag NPs were immobilized on the surface of sand-blasted, large grit, and acid-etched (SLA) @entity4 by manipulating the @entity6 heating effect of @entity3 plasma immersion ion implantation. The @entity3 plasma immersion ion implantation-treated SLA surface gave rise to both good antibacterial activity and excellent compatibility with @entity0 cells. The antibacterial activity rendered by the immobilized Ag NPs was assessed using @entity7 and @entity5 , commonly suspected pathogens for peri-implant disease. The immobilized Ag NPs offered a good defense against multiple cycles of bacteria attack in both @entity7 and @entity5 , and the mechanism was independent of @entity3 release. @entity7 showed a higher susceptibility to Ag NPs than @entity5 , which might be explained by the presence of different wall structures. Moreover, the immobilized Ag NPs had no apparent toxic influence on the viability, proliferation, and differentiation of @entity1 bone marrow mesenchymal stem cells. These results demonstrated that good bactericidal activity could be obtained with very small quantities of immobilized Ag NPs, which were not detrimental to the @entity0 cells involved in the osseointegration process, and promising for @entity4 -based dental implants with commercial SLA surfaces.

title: Hierarchical micro/nanostructured @entity4 with balanced actions to bacterial and XXXX cells for dental implants.

answer: @entity0


abstract: PURPOSE: The purpose of this study was to evaluate the prevalence of comorbidities and adverse events (AEs), and determine the treatment patterns according to @entity6 -sensitivity status in @entity0 with advanced (stage IIIB-IV) or recurrent @entity2 ( @entity2 ). METHODS: A cross-sectional study was carried out in France with @entity0 over 18 years, diagnosed with advanced (stage IIIB-IV) or recurrent @entity2 between 2009 and 2012. A total of 23 physicians (oncologists and gynecologists) participated, contributing 127 @entity0 . Data were abstracted by participating physicians into a case report form. RESULTS: Of the 127 @entity0 included, 92 (72.4%) had advanced @entity2 and 35 (27.6%) had recurrent @entity2 . A total of 73 comorbidities were reported in 44 @entity0 (34.6%). Vascular (10.2%), metabolic (7.1%), respiratory (5.5%), and @entity3 (5.5%) were the most common types of comorbidities reported. Prevalence of AEs was 74.8%, of which 12.6% were classified as serious. The most common AEs were @entity5 (16.5%), hematologic events (12.6%), taste change (11.8%), and @entity1 (7.1%). Throughout the follow-up period, twelve @entity0 @entity4 were reported (six due to disease progression). Of 35 @entity0 with recurrent disease, 16 were highly @entity6 sensitive (recurrence >12 months after stopping @entity6 -based therapy), eleven were partially @entity6 sensitive (recurrence 6-12 months after stopping @entity6 -based therapy), seven were @entity6 resistant (recurrence within 6 months of stopping @entity6 -based therapy or progression while receiving second- or later-line @entity6 -based therapy), and one was @entity6 refractory (recurrence within 6 months from the start of first-line @entity6 -based therapy). CONCLUSION: In this cross-sectional study of advanced and metastatic @entity2 @entity0 , approximately one-third of @entity0 were diagnosed with comorbidities, and approximately three-quarters were diagnosed with AEs (12.6% with severe AEs).

title: Cross-sectional study on comorbidities and adverse events in @entity0 with advanced and recurrent XXXX in France.

answer: @entity2


abstract: PURPOSE: The purpose of this study was to evaluate the prevalence of comorbidities and adverse events (AEs), and determine the treatment patterns according to @entity6 -sensitivity status in @entity0 with advanced (stage IIIB-IV) or recurrent @entity2 ( @entity2 ). METHODS: A cross-sectional study was carried out in France with @entity0 over 18 years, diagnosed with advanced (stage IIIB-IV) or recurrent @entity2 between 2009 and 2012. A total of 23 physicians (oncologists and gynecologists) participated, contributing 127 @entity0 . Data were abstracted by participating physicians into a case report form. RESULTS: Of the 127 @entity0 included, 92 (72.4%) had advanced @entity2 and 35 (27.6%) had recurrent @entity2 . A total of 73 comorbidities were reported in 44 @entity0 (34.6%). Vascular (10.2%), metabolic (7.1%), respiratory (5.5%), and @entity3 (5.5%) were the most common types of comorbidities reported. Prevalence of AEs was 74.8%, of which 12.6% were classified as serious. The most common AEs were @entity5 (16.5%), hematologic events (12.6%), taste change (11.8%), and @entity1 (7.1%). Throughout the follow-up period, twelve @entity0 @entity4 were reported (six due to disease progression). Of 35 @entity0 with recurrent disease, 16 were highly @entity6 sensitive (recurrence >12 months after stopping @entity6 -based therapy), eleven were partially @entity6 sensitive (recurrence 6-12 months after stopping @entity6 -based therapy), seven were @entity6 resistant (recurrence within 6 months of stopping @entity6 -based therapy or progression while receiving second- or later-line @entity6 -based therapy), and one was @entity6 refractory (recurrence within 6 months from the start of first-line @entity6 -based therapy). CONCLUSION: In this cross-sectional study of advanced and metastatic @entity2 @entity0 , approximately one-third of @entity0 were diagnosed with comorbidities, and approximately three-quarters were diagnosed with AEs (12.6% with severe AEs).

title: Cross-sectional study on comorbidities and adverse events in XXXX with advanced and recurrent @entity2 in France.

answer: @entity0


abstract: PURPOSE: To evaluate how the growth of @entity4 elsewhere (NVE) was delineated in an eye with @entity5 (CRVO) using optical coherence tomography (OCT) angiography. @entity0 AND METHODS: We examined a 64-year-old @entity0 diagnosed with hemi-CRVO. The area around the occluded vein was scanned using a spectral-domain OCT device (RTVue XR Avanti). Blood flow was detected using the split-spectrum amplitude-decorrelation angiography (SSADA) algorithm. Color fundus photography, @entity1 angiography (FA), and OCT angiography examinations were performed at the first visit and at 3 and 6 months postpresentation. RESULTS: At the first visit, FA revealed delayed retinal @entity3 and extensive areas of capillary nonperfusion. The @entity0 underwent a trial of intravitreal ranibizumab injection (0.5 mg/0.05 mL) for the treatment of @entity2 . At 3 months postpresentation, there was no NVE around the occluded vein in the en-face SSADA image, but at 6 months, NVE appeared on the occluded veins. The en-face SSADA image showed the NVE structure in the fibrovascular membrane on the occluded vein more clearly than FA images. CONCLUSION: OCT angiography clearly visualized the sprouting of NVE in an eye with hemi-CRVO. New findings of the vascular structure of NVE in hemi-CRVO were revealed using the en-face SSADA algorithm.

title: En-face optical coherence tomography angiography of XXXX elsewhere in @entity5 .

answer: @entity4


abstract: PURPOSE: To evaluate how the growth of @entity4 elsewhere (NVE) was delineated in an eye with @entity5 (CRVO) using optical coherence tomography (OCT) angiography. @entity0 AND METHODS: We examined a 64-year-old @entity0 diagnosed with hemi-CRVO. The area around the occluded vein was scanned using a spectral-domain OCT device (RTVue XR Avanti). Blood flow was detected using the split-spectrum amplitude-decorrelation angiography (SSADA) algorithm. Color fundus photography, @entity1 angiography (FA), and OCT angiography examinations were performed at the first visit and at 3 and 6 months postpresentation. RESULTS: At the first visit, FA revealed delayed retinal @entity3 and extensive areas of capillary nonperfusion. The @entity0 underwent a trial of intravitreal ranibizumab injection (0.5 mg/0.05 mL) for the treatment of @entity2 . At 3 months postpresentation, there was no NVE around the occluded vein in the en-face SSADA image, but at 6 months, NVE appeared on the occluded veins. The en-face SSADA image showed the NVE structure in the fibrovascular membrane on the occluded vein more clearly than FA images. CONCLUSION: OCT angiography clearly visualized the sprouting of NVE in an eye with hemi-CRVO. New findings of the vascular structure of NVE in hemi-CRVO were revealed using the en-face SSADA algorithm.

title: En-face optical coherence tomography angiography of @entity4 elsewhere in XXXX .

answer: @entity5


abstract: PURPOSE: Urinary extravasation at the @entity1 is common after radical prostatectomies. Nevertheless, no data exist referring to the optimal date of catheter removal at the time of expected complete @entity3 of the leakage. Thus, we developed over the last 10 years a standardized concept to check the @entity1 , evaluating urinary extravasation using a dynamic transrectal ultrasound ( @entity5 ). METHODS: From 1999 to 2008, 1,479 radical prostatectomies have been performed. For complete @entity3 , 752 could be evaluated using the standardized concept of checking the @entity1 . The first 250 @entity0 have been evaluated by cystogram and @entity5 and the following 502 @entity0 only by @entity5 postoperatively. The date of checking the @entity1 was determined by the urine color. RESULTS: Urinary extravasation could be detected 4-8 days postoperatively in 41% (n = 308), 9-12 days in 16% (n = 120), 13-20 days in 8% (n = 60), and in no @entity0 after 21 days. The coefficient of correlation comparing @entity5 versus cystogram was r = 0.99, P < 0.05. The measured volume of urinary extravasation after 4-8 days postoperatively was 15 ml (3-49 ml) using @entity5 and 16 ml (3-45 ml) using cystogram. After 9-20 days, the volume was determined as 9 ml (3-24 ml) by @entity5 and 9 ml (4-23 ml) by cystogram. The macroscopic evaluation of the urinary color was very well correlated with the likelihood of extravasation being still present. When the urine was cloudy or colored by old blood, extravasation was present in 96.9% of the @entity0 . Microscopic evaluation like leukocyturia or @entity2 of the urine on the same day shows specificity in only 34.3%. CONCLUSIONS: Following radical prostatectomy, the urine color is essential to assess the chance of a persisting leakage at the @entity1 . The method of @entity5 can replace the cystogram in checking for complete healing of the @entity1 , thus decreasing the exposure to @entity4 of the @entity0 of about 60 cGy/cm(2).

title: New standardization of checking the vesicourethral XXXX for @entity3 following radical prostatectomy with dynamic transrectal ultrasound: can this new technique replace the traditional postoperative cystogram?

answer: @entity1


abstract: PURPOSE: Urinary extravasation at the @entity1 is common after radical prostatectomies. Nevertheless, no data exist referring to the optimal date of catheter removal at the time of expected complete @entity3 of the leakage. Thus, we developed over the last 10 years a standardized concept to check the @entity1 , evaluating urinary extravasation using a dynamic transrectal ultrasound ( @entity5 ). METHODS: From 1999 to 2008, 1,479 radical prostatectomies have been performed. For complete @entity3 , 752 could be evaluated using the standardized concept of checking the @entity1 . The first 250 @entity0 have been evaluated by cystogram and @entity5 and the following 502 @entity0 only by @entity5 postoperatively. The date of checking the @entity1 was determined by the urine color. RESULTS: Urinary extravasation could be detected 4-8 days postoperatively in 41% (n = 308), 9-12 days in 16% (n = 120), 13-20 days in 8% (n = 60), and in no @entity0 after 21 days. The coefficient of correlation comparing @entity5 versus cystogram was r = 0.99, P < 0.05. The measured volume of urinary extravasation after 4-8 days postoperatively was 15 ml (3-49 ml) using @entity5 and 16 ml (3-45 ml) using cystogram. After 9-20 days, the volume was determined as 9 ml (3-24 ml) by @entity5 and 9 ml (4-23 ml) by cystogram. The macroscopic evaluation of the urinary color was very well correlated with the likelihood of extravasation being still present. When the urine was cloudy or colored by old blood, extravasation was present in 96.9% of the @entity0 . Microscopic evaluation like leukocyturia or @entity2 of the urine on the same day shows specificity in only 34.3%. CONCLUSIONS: Following radical prostatectomy, the urine color is essential to assess the chance of a persisting leakage at the @entity1 . The method of @entity5 can replace the cystogram in checking for complete healing of the @entity1 , thus decreasing the exposure to @entity4 of the @entity0 of about 60 cGy/cm(2).

title: New standardization of checking the vesicourethral @entity1 for XXXX following radical prostatectomy with dynamic transrectal ultrasound: can this new technique replace the traditional postoperative cystogram?

answer: @entity3


abstract: The immunoperoxidase technique, using antibodies against @entity0 urinary urokinase (Mr 55,000), was used for the localization of this enzyme in histological preparations of @entity0 @entity6 and normal colon tissue. The localization of tissue (vascular) activator was also investigated using antibodies against enzyme purified from @entity0 @entity3 . Both the "indirect method" and the peroxidase-antiperoxidase technique were found to be useful. Urokinase-reactive material was found in all tissues examined (33 primary @entity2 , 11 @entity1 , and 8 @entity5 ). In the normal colon, urokinase was found only in some of the goblet cells of the mucosal epithelium. In @entity6 , diffuse specific staining was observed in the cytoplasm, but the most intense staining was localized at the edge of the @entity2 cells bordering the lumen of the glands. In some cases, intense supranuclear staining could be observed in a location corresponding to the Golgi apparatus. In a few instances, urokinase could be seen associated with fibroblasts near the advancing front of an invading @entity2 . @entity5 , a @entity2 but often a precursor of @entity2 , also showed the presence of urokinase. Most significant were the observations showing that, in regions of the mucosal glands where normal epithelial cells were abruptly replaced by @entity2 cells, the appearance of cytoplasmic urokinase showed strict and exclusive association with the malignant cells, and the same was the case in transitions from normal epithelium to @entity5 . In contrast to urokinase, @entity7 was not associated with @entity2 cells, but was consistently present in the stroma which separates the @entity2 glands and was localized in the endothelium of the blood vessels. This visual evidence was supported by results of extraction of plasminogen activators from @entity2 , and from the separated mucosal and submucosal layers of the normal colon of the same @entity0 , which showed that urokinase is most abundant in the @entity2 tissue and least abundant in the submucosa, while tissue activator is most prevalent in the well-vascularized mucosa and submucosa and scarce in the usually poorly vascularized @entity4 .

title: Localization of plasminogen activators in @entity0 XXXX by immunoperoxidase staining.

answer: @entity6


abstract: The immunoperoxidase technique, using antibodies against @entity0 urinary urokinase (Mr 55,000), was used for the localization of this enzyme in histological preparations of @entity0 @entity6 and normal colon tissue. The localization of tissue (vascular) activator was also investigated using antibodies against enzyme purified from @entity0 @entity3 . Both the "indirect method" and the peroxidase-antiperoxidase technique were found to be useful. Urokinase-reactive material was found in all tissues examined (33 primary @entity2 , 11 @entity1 , and 8 @entity5 ). In the normal colon, urokinase was found only in some of the goblet cells of the mucosal epithelium. In @entity6 , diffuse specific staining was observed in the cytoplasm, but the most intense staining was localized at the edge of the @entity2 cells bordering the lumen of the glands. In some cases, intense supranuclear staining could be observed in a location corresponding to the Golgi apparatus. In a few instances, urokinase could be seen associated with fibroblasts near the advancing front of an invading @entity2 . @entity5 , a @entity2 but often a precursor of @entity2 , also showed the presence of urokinase. Most significant were the observations showing that, in regions of the mucosal glands where normal epithelial cells were abruptly replaced by @entity2 cells, the appearance of cytoplasmic urokinase showed strict and exclusive association with the malignant cells, and the same was the case in transitions from normal epithelium to @entity5 . In contrast to urokinase, @entity7 was not associated with @entity2 cells, but was consistently present in the stroma which separates the @entity2 glands and was localized in the endothelium of the blood vessels. This visual evidence was supported by results of extraction of plasminogen activators from @entity2 , and from the separated mucosal and submucosal layers of the normal colon of the same @entity0 , which showed that urokinase is most abundant in the @entity2 tissue and least abundant in the submucosa, while tissue activator is most prevalent in the well-vascularized mucosa and submucosa and scarce in the usually poorly vascularized @entity4 .

title: Localization of plasminogen activators in XXXX @entity6 by immunoperoxidase staining.

answer: @entity0


abstract: The ascending projections of the mammillary region of the hypothalamus and adjacent posterolateral hypothalamus were investigated by autoradiographic and horseradish peroxidase histochemical techniques. Analysis of the anterograde data revealed that the main contingent of mammillary fibers ascends in the medial forebrain bundle (MFB) in the lateral hypothalamic area. These fibers distribute to a number of @entity1 regions via three pathways. (1) Fibers course dorsomedially into the medial and lateral parts of the septum and continue into the hippocampus with a dense terminal field in the parahippocampal area. (2) Laterally coursing fibers project to area corticoidea dorsolateralis, area temporo-parieto-occipitalis, cortex piriformis, and the posterior part of archistriatum. (3) The fibers remaining in the MFB ascend into the "ventral paleostriatum," olfactory tubercle, and into the lateral and ventral borders of the rostral portion of lobus parolfactorius (LPO). Numerous fibers leave the LPO region and course dorsally into the deep layer of the Wulst, @entity2 ( @entity2 ). Many fibers continue dorsolaterally through the @entity2 and enter an unnamed region of the dorsolateral telencephalon (lateral to the vallecula) at the level of the olfactory bulb. Retrograde transport experiments revealed that the perikarya of origin-of-fiber projections to the parahippocampal area and to the rostral, dorsolateral telencephalon reside not only in nucleus mammillaris lateralis but also in posterolateral hypothalamic cells rostral and dorsal to this nucleus. The projection of these hypothalamic cells to the hippocampal formation and many other @entity1 regions in birds suggests that these cells are similar to the @entity0 supramammillary nucleus and posterolateral hypothalamus rather than the mammillary nuclei.

title: Ascending projections of the mammillary region in the pigeon: emphasis on XXXX connections.

answer: @entity1


abstract: BACKGROUND: This study retrospectively describes the outcome of a series of 38 @entity0 (pts) with T4 @entity2 exclusively treated by radio and chemotherapy. @entity0 AND METHODS: From 1992 to 2007, 38 pts with UST4-N0-2-M0 @entity2 were treated with exclusive radiotherapy and chemotherapy. All @entity0 received external beam radiotherapy (EBRT) (median dose 45   Gy) with a concomitant chemotherapy (5- @entity4 - @entity3 ). Eleven @entity0 received neo-adjuvant chemotherapy (5- @entity4 - @entity3 ). After 2-8 weeks, a 15-20   Gy boost was delivered either with EBRT (20 pts) or interstitial (192)Ir brachytherapy (18 pts). Mean follow-up was 66 months. RESULTS: After chemoradiation therapy (CRT), 13 pts (34%) had a complete response, 23 pts (60%) a response >50% (2 pts were not evaluated). The 5-year-disease-free survival was 79.2        6.5%, and the 5-year overall survival was 83.9        6%. Eight @entity0 developed @entity1 progression (mean delay 8.8 months), six of them requiring a salvage surgery with definitive colostomy for local relapse. Late severe complication requiring colostomy was observed in 2 pts. The 5-year-colostomy-free survival was 78        6.9%. @entity0 who received primary chemotherapy had a statistically significant better 5-year colostomy-free survival (100% vs. 38        16.4%, P   =   0.0006). CONCLUSION: T4 @entity2 can be treated with a curative intent using a sphincter-sparing approach of CRT, and neo-adjuvant chemotherapy should be considered prior to radiotherapy.

title: Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 XXXX ?

answer: @entity2


abstract: @entity4 , LQTS, results in serious @entity1 , such as @entity3 and @entity5 . A promiscuous binding of different drugs to the intracavitary binding site in the pore domain (PD) of @entity0 ether-a-go-go related gene ( @entity6 ) channels leads to a similar dysfunction, known as a drug-induced LQTS. Therefore, an assessment of the blocking ability for potent drugs is of great pragmatic value for molecular pharmacology and medicinal chemistry of hERGs. Thus, we attempted to create an in silico model aimed at blinded drug screening for their blocking ability to the @entity7 PD. Two distinct approaches to the drug blockage, ligand-based QSAR and receptor-based molecular docking methods, are combined for development of a universal pharmacophore model, which provides rapid assessment of drug blocking ability to the @entity7 channel. The best 3D-QSAR model (AAADR.7) from PHASE modeling was selected from a pool consisting of 44 initial candidates. The constructed model using 31 @entity6 blockers was validated with 9 test set compounds. The resulting model correctly predicted the pIC(50) values of test set compounds as true unknowns. To further evaluate the pharmacophore model, 14 @entity6 blockers with diverse @entity6 blocking potencies were selected from literature and they were used as additional external blind test sets. The resulting average deviation between in vitro and predicted pIC(50) values of external test set blockers is found as 0.29 suggesting that the model is able to accuretely predict the pIC(50) values as true unknowns. These pharmacophore models were merged with a previously developed atomistic receptor model for the @entity7 PD and exhibited a high consistency between ligand-based and receptor-based models. Therefore, the developed 3D-QSAR model provides a predictive tool for profiling candidate compounds before their synthesis. This model also indicated the key functional groups determining a high-affinity blockade of the @entity7 channel. To cross-validate consistency between the constructed @entity7 pore domain and the pharmacophore models, we performed docking studies using the homology model of @entity7 . To understand how polar or nonpolar moieties of inhibitors stimulate channel inhibition, critical @entity2 replacement (i.e., T623, S624, S649, Y652 and F656) at the @entity6 cavity was examined by in silico mutagenesis. The average docking score differences between wild type and mutated @entity6 channels was found to have the following order: @entity9 > @entity8 > @entity11 > @entity10 > @entity12 . These results are in agreement with experimental data.

title: Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the XXXX pore domain.

answer: @entity7


abstract: The purpose of the follow-up study was to determine whether modern therapy with @entity5 and/or valproate with/without @entity1 and its derivatives improves the longterm prognosis of @entity4 as compared to formerly used treatments. The @entity0 population consisted of 194 cases (88 @entity0 , 106 @entity0 ) with spike wave @entity2 starting with absences. In each case the diagnosis was confirmed by clinical observation and the typical EEG pattern. Only those @entity0 were included who could be followed beyond the eighteenth year of life (up to age 45). The sample includes also older @entity0 diagnosed during the fifties, before the present standard therapy was available. Because of the heterogeneity of the material and its selection, the data obtained are not suited to make a general statement about the ultimate prognosis of absences. The results demonstrate the effectiveness of regularly applied modern treatment. 72 out of 194 @entity0 (37%) manifested generalized @entity3 (gtcs) during the course: 20 of these @entity0 showed only incidental generalized @entity3 , which were not dependent on therapy. In 52 cases gtcs appeared without relation to precipitating factors. None of these @entity0 received regular standard therapy before onset of gtcs. In 31 cases absence statuses were observed. These @entity0 did not have an unfavourable outcome provided the standard therapy was instituted early and consequently. A change from @entity4 into an @entity2 with complex partial @entity3 sensu strictiori could not be observed. At final investigation 42 of 194 @entity0 still had @entity3 : 7 with absences, 35 with grand mal with or without absences.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Longterm follow-up of childhood @entity2 with absences. I. XXXX with absences at onset.

answer: @entity2


abstract: The purpose of the follow-up study was to determine whether modern therapy with @entity5 and/or valproate with/without @entity1 and its derivatives improves the longterm prognosis of @entity4 as compared to formerly used treatments. The @entity0 population consisted of 194 cases (88 @entity0 , 106 @entity0 ) with spike wave @entity2 starting with absences. In each case the diagnosis was confirmed by clinical observation and the typical EEG pattern. Only those @entity0 were included who could be followed beyond the eighteenth year of life (up to age 45). The sample includes also older @entity0 diagnosed during the fifties, before the present standard therapy was available. Because of the heterogeneity of the material and its selection, the data obtained are not suited to make a general statement about the ultimate prognosis of absences. The results demonstrate the effectiveness of regularly applied modern treatment. 72 out of 194 @entity0 (37%) manifested generalized @entity3 (gtcs) during the course: 20 of these @entity0 showed only incidental generalized @entity3 , which were not dependent on therapy. In 52 cases gtcs appeared without relation to precipitating factors. None of these @entity0 received regular standard therapy before onset of gtcs. In 31 cases absence statuses were observed. These @entity0 did not have an unfavourable outcome provided the standard therapy was instituted early and consequently. A change from @entity4 into an @entity2 with complex partial @entity3 sensu strictiori could not be observed. At final investigation 42 of 194 @entity0 still had @entity3 : 7 with absences, 35 with grand mal with or without absences.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Longterm follow-up of childhood XXXX with absences. I. @entity2 with absences at onset.

answer: @entity2


abstract: BACKGROUND: @entity2 shares some ethiopathological features with @entity3 and increasing evidence links Toll-like receptors (TLRs) to atherogenesis. METHODS: TLR-mediated @entity1 and osteogenesis were investigated in @entity0 interstitial cells isolated from stenotic and non-stenotic aortic valves. TLR expression and signalling were evaluated by quantitative RT-PCR, flow cytometry, Western blot analysis, ELISA, and cytokine arrays. Osteogenesis was evaluated by measuring alkaline phosphatase activity. RESULTS: Interstitial cells from control valves express most TLRs, being @entity8 the most abundant, whereas cells from stenotic valves express higher @entity8 and @entity7 and lower @entity11 and @entity10 transcript levels. When pro-inflammatory pathways were analyzed, we observed that @entity8 , @entity7 and @entity9 ligands induced an early activation of NF-kB and @entity4 MAPK activation in cells from control and stenotic valves. Strikingly, when TLRs sensing viral patterns were studied, a sustained @entity9 -mediated activation of NF-kB, a kB-independent induction of catalytically active @entity6 and @entity5 expression, and induction of expression of several chemokines were observed. @entity8 , but not @entity7 , engagement produced a similar but NF-kB-dependent effect. Moreover, @entity9 and @entity8 agonists induced alkaline phosphatase expression and activity. CONCLUSIONS: Exposure of aortic valve interstitial cells to viral and Gram-negative bacteria molecular patterns induces distinct and long-term TLR-mediated pro-inflammatory and pro-osteogenic responses that might be relevant to the pathogenesis of @entity2 .

title: Viral and bacterial patterns induce TLR-mediated sustained XXXX and calcification in aortic valve interstitial cells.

answer: @entity1


abstract: BACKGROUND: The optimal management of the @entity0 requiring cardiac surgery with concomitant severe @entity3 remains a controversy. The traditional approach involves staged or combined carotid endarterectomy and cardiac surgery. This study evaluated the feasibility and safety of angioplasty and stenting for the treatment of @entity7 concomitantly to cardiac operations to reduce the risk of perioperative @entity2 . METHODS: All @entity0 scheduled for cardiac surgery were screened preoperatively by color duplex ultrasonography for @entity3 . Carotid stenoses >= 60% in symptomatic @entity0 and >= 70% in asymptomatic @entity0 were treated using @entity10 ( @entity10 ) under local anesthesia immediately before the open heart surgery. Cerebral protection devices were used in all cases. @entity0 did not receive @entity4 or @entity9 before the procedure. In a prospective, nonrandomized study, we analyzed 90 consecutive @entity0 requiring cardiac surgery with concomitant severe carotid @entity6 who underwent one stage @entity10 and cardiac surgery. RESULTS: Despite the high baseline risk profile, our results were encouraging. Carotid stenting was successful in all @entity0 . No @entity1 occurred during the carotid stenting procedures. The 30-day death/ @entity2 rate was 2.2% (one death, one @entity2 ). No @entity8 occurred. The carotid restenosis rate was zero during the intermediate-term follow-up. CONCLUSIONS: In our experience, @entity10 followed immediately by cardiac surgery is safe and represents a reasonable option for selected @entity0 presenting with severe carotid and @entity5 .

title: Synchronous XXXX and open heart surgery.

answer: @entity10


abstract: BACKGROUND: @entity2 jirovecii (PJ), a pathogenic fungus, causes severe @entity1 ( @entity1 ) among immunocompromised @entity0 . A laboratory-developed real-time polyermase chain reaction (PCR) assay was validated for PJ detection to improve diagnosis of @entity1 . METHODS: Forty stored bronchoalveolar lavage (BAL) samples (20 known PJ positive [PJ+] and 20 known PJ negative [PJ-]) were initially tested using the molecular assay. Ninety-two sequentially collected BAL samples were then analyzed using an immunofluorescence assay (IFA) and secondarily tested using the PJ real-time PCR assay. Discrepant results were resolved by retesting BAL samples using another real-time PCR assay with a different target. PJ real-time PCR assay performance was compared with the existing gold standard (ie, IFA) and a modified gold standard, in which a true positive was defined as a sample that tested positive in two of three methods in a @entity0 suspected to have @entity1 . RESULTS: Ninety of 132 (68%) BAL fluid samples were collected from immunocompromised @entity0 . Thirteen of 92 (14%) BALs collected were PJ+ when tested using IFA. A total of 40 BAL samples were PJ+ in the present study including: all IFA positive samples (n=13); all referred PJ+ BAL samples (n=20); and seven additional BAL samples that were IFA negative, but positive using the modified gold standard. Compared with IFA, the PJ real-time PCR had sensitivity, specificity, and positive and negative predictive values of 100%, 91%, 65% and 100%, respectively. Compared with the modified gold standard, PJ real-time PCR had a sensitivity, specificity, and positive and negative predictive values of 100%. CONCLUSION: PJ real-time PCR improved detection of PJ in immunocompromised @entity0 .

title: Development and validation of a XXXX jirovecii real-time polymerase chain reaction assay for diagnosis of @entity1 .

answer: @entity2


abstract: BACKGROUND: @entity2 jirovecii (PJ), a pathogenic fungus, causes severe @entity1 ( @entity1 ) among immunocompromised @entity0 . A laboratory-developed real-time polyermase chain reaction (PCR) assay was validated for PJ detection to improve diagnosis of @entity1 . METHODS: Forty stored bronchoalveolar lavage (BAL) samples (20 known PJ positive [PJ+] and 20 known PJ negative [PJ-]) were initially tested using the molecular assay. Ninety-two sequentially collected BAL samples were then analyzed using an immunofluorescence assay (IFA) and secondarily tested using the PJ real-time PCR assay. Discrepant results were resolved by retesting BAL samples using another real-time PCR assay with a different target. PJ real-time PCR assay performance was compared with the existing gold standard (ie, IFA) and a modified gold standard, in which a true positive was defined as a sample that tested positive in two of three methods in a @entity0 suspected to have @entity1 . RESULTS: Ninety of 132 (68%) BAL fluid samples were collected from immunocompromised @entity0 . Thirteen of 92 (14%) BALs collected were PJ+ when tested using IFA. A total of 40 BAL samples were PJ+ in the present study including: all IFA positive samples (n=13); all referred PJ+ BAL samples (n=20); and seven additional BAL samples that were IFA negative, but positive using the modified gold standard. Compared with IFA, the PJ real-time PCR had sensitivity, specificity, and positive and negative predictive values of 100%, 91%, 65% and 100%, respectively. Compared with the modified gold standard, PJ real-time PCR had a sensitivity, specificity, and positive and negative predictive values of 100%. CONCLUSION: PJ real-time PCR improved detection of PJ in immunocompromised @entity0 .

title: Development and validation of a @entity2 jirovecii real-time polymerase chain reaction assay for diagnosis of XXXX .

answer: @entity1


abstract: BACKGROUND: Psychological profile of @entity1 @entity0 is not well studied in Iran. We investigated the psychological status of Iranian @entity0 with @entity2 ( @entity2 ) and its relationship with disease activity and quality of life (QOL). MATERIALS AND METHODS: A cross-sectional study was conducted on adult @entity2 @entity0 . The Lichtiger Colitis Activity Index, Hospital @entity3 and @entity4 Scale, General Health Questionnaire-12, and WHOQOL-BREF, were completed by the @entity0 . RESULTS: From 120 studied @entity0 , 35 (29.2%), 48 (40.0%), and 46 (38.3%) had significant @entity3 , @entity4 , and @entity5 , respectively. @entity3 , @entity4 , and @entity5 were strongly correlated with disease activity (r = 0.357 to 0.439, P < 0.01). Disease activity was negatively correlated with all QOL dimensions (r = -0.245 to -0.550, P < 0.01). @entity3 , @entity4 , and @entity5 were also negatively correlated with all QOL domains (r = -0.356 to -0.789, P < 0.01). In the regression models, @entity3 was independently associated with active disease (b = 4.150, P = 0.049). Furthermore, disease activity was associated with the physical health (b = -0.371, P < 0.001). For almost all of the QOL domains, @entity4 and @entity5 were independent predictors (b = -0.296 to -0.453, P < 0.001). CONCLUSION: @entity3 , @entity4 , and @entity5 are highly frequent in @entity2 @entity0 of our society and are strongly associated with disease activity. @entity4 and @entity5 are important predictors of poor QOL in these @entity0 . Further prospective studies, as well as clinical trials, are warranted in this regard.

title: Psychological status in Iranian @entity0 with XXXX and its relation to disease activity and quality of life.

answer: @entity2